Patents by Inventor Jochen Bodem

Jochen Bodem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230302075
    Abstract: Compositions may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Coronaviridae family and wherein the composition includes an extract of black currants and/or bilberries. The black currants may be the fruit of Ribes nigrum, and/or the bilberries may be the fruit of Vaccinium myrtillus. The extract may be of the pomaces of the black currants and/or the bilberries.
    Type: Application
    Filed: June 18, 2021
    Publication date: September 28, 2023
    Applicant: Evonik Operations GmbH
    Inventors: Jean-Luc HERBEAUX, Norbert WINDHAB, Christoph BRÜCHER, Anne BENEDIKT, Maria STEINKE, Jochen BODEM
  • Publication number: 20220184163
    Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Paramyxoviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio in a range of from 0.5:1 to 1:0.5. The extract may be an alcoholic extract, such as a methanol extract. The composition may be administered to the subject 1 to 10 oral dosages of at least 80 mg anthocyanins each per day, preferably 3 to 6 oral dosages of at least 80 mg anthocyanins each per day. The subject may not have received a measles vaccination or have previously been exposed to the measles virus.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Applicant: Evonik Operations GmbH
    Inventors: Jean-Luc HERBEAUX, Norbert WINDHAB, Anne BENEDIKT, Andrea ENGEL, Maria STEINKE, Jochen BODEM
  • Publication number: 20220184164
    Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Herpesviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio of 0.5:1 to 1:0.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Applicant: Evonik Operations GmbH
    Inventors: Jean-Luc HERBEAUX, Norbert WINDHAB, Christoph BRÜCHER, Anne BENEDIKT, Maria STEINKE, Jochen BODEM
  • Publication number: 20220184162
    Abstract: The present invention is related to composition for use in treating or preventing a cancer in a subject, wherein the cancer comprises cancer cells that are CD4+, and wherein the composition comprises one or more of an extract of black currants, an extract of bilberries, and an anthocyanin.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Applicant: Evonik Operations GmbH
    Inventors: Jean-Luc HERBEAUX, Norbert WINDHAB, Christoph BRÜCHER, Anne BENEDIKT, Maria STEINKE, Jochen BODEM, Wolfgang SCHAMEL
  • Publication number: 20220175720
    Abstract: Combined preparations including an anthocyanin composition and an antiviral agent for use in treating or preventing a virus infection in a subject, wherein the anthocyanin composition includes an extract of black currants, an extract of bilberries, an extract of red grapes, and/or delphinidin 3 glucoside, wherein the virus is from the Herpesviridae family and the antiviral agent is a Herpesviridae antiviral agent, and wherein the anthocyanin composition and the antiviral agent are for simultaneous, separate or sequential use.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Applicant: Evonik Operations GmbH
    Inventors: Jean-Luc HERBEAUX, Norbert WINDHAB, Christoph BRÜCHER, Anne BENEDIKT, Andrea ENGEL, Maria STEINKE, Jochen BODEM
  • Publication number: 20220175809
    Abstract: The present invention is related to Delphinidin-3-glucoside (D3G) for use in treating or preventing a vims infection in a subject, wherein the virus is from the Herpesviridae family.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Applicant: Evonik Operations GmbH
    Inventors: Jean-Luc HERBEAUX, Norbert WINDHAB, Christoph BRÜCHER, Anne BENEDIKT, Andrea ENGEL, Maria STEINKE, Jochen BODEM
  • Patent number: 8013190
    Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: September 6, 2011
    Assignees: Vysoka Skola Chemicko-Technologicka V Praze, Ustav Organicke Chemie A Biochemie AV CZ, Ustav Anorganicke Chemie AV CZ, Department of Virology, University of Heidelberg
    Inventors: Vladimír Král, Petr Cigler, Jan Konvalinka, Milan Kozísek, Jana Prejdová, Bohumír Grüner, Jaromír Plesek, Martin Lepsík, Jana Pokorná, Hans-Georg Kräusslich, Jochen Bodem
  • Publication number: 20090012044
    Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.
    Type: Application
    Filed: January 27, 2005
    Publication date: January 8, 2009
    Applicants: VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE, USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CZ, USTAV ANORGANICKE CHEMIE AV CZ, DEPARTMENT OF VIROLOGY, UNIVERSITY OF HEIDELBERG
    Inventors: Vladimir Kral, Petr Cigler, Jan Konvalinka, Milan Kozisek, Jana Prejdova, Bohumir Gruner, Jaromir Plesek, Martin Lepsik, Jana Pokorna, Hans-Georg Krausslich, Jochen Bodem